Inhibition of proliferation and apoptosis induced by a Na+/H+ exchanger-1 (NHE-1) antisense gene on drug-resistant human small cell lung cancer cells

Oncology Reports

Volumn 21, Issue 5, 2009, Pages 1243-1249

  Li, Shujun ^a   Bao, Pengtao ^a   Li, Zhikui ^a   Ouyang, H F ^a   Wu, Changgui ^a   Qian, Guisheng ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antisense gene; Drug resistance; NHE 1; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE SODIUM PROTON EXCHANGE PROTEIN 1; CASPASE 3; CISPLATIN; ETOPOSIDE; FLUOROURACIL; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ANTISENSE THERAPY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE; CELL PH; CONTROLLED STUDY; EXPRESSION VECTOR; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MITOSIS INHIBITION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECTROFLUOROMETRY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; HUMANS; HYDROGEN-ION CONCENTRATION; LUNG NEOPLASMS; RNA, ANTISENSE; RNA, MESSENGER; SMALL CELL LUNG CARCINOMA; SODIUM-HYDROGEN ANTIPORTER; TRANSFECTION;

EID: 67649365855     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000347     Document Type: Article

References (41)

1. De Jong WK, Groen HJ, Koolen MG, Biesma B, Willems LN, Kwa HB, van Bochove A, van Tinteren H and Smit EF: Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer. Eur J Cancer 43: 2345-2350, 2007.
2. Fischer B, Marinov M and Arcaro A: Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? Cancer Treat Rev 33: 391-406, 2007.
3. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, Warner RB, Ng SC, Fesik SW, Elmore SW, Rosenberg SH and Tse C: Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 67: 1176-1183, 2007.
4. Hodkinson PS, Mackinnon AC and Sethi T: Extracellular matrix regulation of drug resistance in small-cell lung cancer. Int J Radiat Biol 83: 733-741, 2007.
5. Rintoul RC and Sethi T: The role of extracellular matrix in small-cell lung cancer. Lancet Oncol 2: 437-442, 2001.
6. Joseph MG, Banerjee D, Kocha W, Feld R, Stitt LW and Cherian MG: Metallothionein expression in patients with small cell carcinoma of the lung: correlation with other molecular markers and clinical outcome. Cancer 92: 836-842, 2001.
7. Tsurutani J, Soda H, Oka M, Suenaga M, Doi S, Nakamura Y, Nakatomi K, Shiozawa K, Amada YY, Kamihira S and Kohno S: Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines. Int J Cancer 104: 238-242, 2003.
8. Triller N, Korosec P, Kern I, Kosnik M and Debeljak A: Multi-drug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer 54: 235-240, 2006.
9. Chan DC, Geraci M and Bunn PA Jr: Anti-growth factor therapy for lung cancer. Drug Resist Updat 1: 377-388, 1998.
10. Krystal GW, Sulanke G and Litz J: Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 1: 913-922, 2002.
11. Ferraldeschi R, Baka S, Jyoti B, Faivre-Finn C, Thatcher N and Lorigan P: Modern management of small-cell lung cancer. Drugs 67: 2135-2152, 2007.
12. + exchanger 1 (NHE1): functional and clinical implications. J Biol Chem 282: 37854-37863, 2007.
13. Wahl ML, Owen JA, Burd R, Herlands RA, Nogami SS, Rodeck U, Berd D, Leeper DB and Owen CS: Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther 1: 617-628, 2002.
14. Binnie MC, Alexander FE, Heald C and Habib FK: Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer. Prostate 63: 309-315, 2005.
15. Khaled AR, Moor AN, Li A, Kim K, Ferris DK, Muegge K, Fisher RJ, Fliegel L and Durum SK: Trophic factor withdrawal: p38 mitogen-activated protein kinase activates NHE1, which induces intracellular alkalinization. Mol Cell Biol 21: 7545-7557, 2001.
16. + exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem 279: 26991-27007, 2004.
17. + antiporter during cell volume regulation. Evidence for a phosphorylation-independent mechanism. J Biol Chem 267: 23823-23828, 1992.
18. + exchanger 1 allosteric balance by its localization in cholesterol- and caveolin-rich membrane microdomains. J Cell Physiol 216: 207-220, 2008.
19. Pederson SF, Varming C, Christensen ST and Hoffmann EK: Mechanisms of activation of NHE by cell shrinkage and by calyculin A in Ehrlich ascites tumor cells. J Membr Biol 189: 67-81, 2002.
20. Lagana A, Vadnais J, Le PU, Nguyen TN, Laprade R, Nabi IR and Noel J: Regulation of the formation of tumor cell pseudopodia by the Na(+)/H(+) exchanger NHE1. J Cell Sci 113 (Pt 20): 3649-3662, 2000.
21. Zhao R, Oxley D, Smith TS, Follows GA, Green AR and Alexander DR: DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH. PLoS Biol 5: e1, 2007.
22. McLean LA, Roscoe J, Jorgensen NK, Gorin FA and Cala PM: Malignant gliomas display altered pH regulation by NHE1 compared with non-transformed astrocytes. Am J Physiol 278: C676-C688, 2000.
23. Shen MR, Wilkins RJ, Chou CY and Ellory JC: Anion exchanger isoform 2 operates in parallel with Na(+)/H(+) exchanger isoform 1 during regulatory volume decrease of human cervical cancer cells. FEBS Lett 512: 52-58, 2002.
24. Popat S and O'Brien M: Chemotherapy strategies in the treatment of small cell lung cancer. Anticancer Drugs 16: 361-372, 2005.
25. Einhorn LH, Crawford J, Birch R, Omura G, Johnson DH and Greco FA: Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. J Clin Oncol 6: 451-456, 1988.
26. Evans WK, Feld R, Murray N, et al: The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer. Semin Oncol 13: 10-16, 1986.
27. Wangpaichitr M, Wu C, You M, Kuo MT, Feun L, Lampidis T and Savaraj N: Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol 591: 124-127, 2008.
28. Ji FY, Qian GS, Qian P, Chen Y, Guo RL, Li SP and Huang GJ: Involvement of bcl-2 in multidrug resistance in human small cell lung cancer cell subline H446/DDP. Chin J Tuberc Respir Dis 29: 156-160, 2006.
29. Liu LZ, Qian GS and Zhou XD: Expression of a new lung cancer drug resistance-related gene in lung cancer tissues and lung cancer cell strains. Chin J Cancer 22: 171-174, 2003.
30. Midoux P, Breuzard G, Gomez JP and Pichon C: Polymer-based gene delivery: a current review on the uptake and intracellular trafficking of polyplexes. Curr Gene Ther 8: 335-352, 2008.
31. Pouyssegur J, Franchi A and Pages G: pHi, aerobic glycolysis and vascular endothelial growth factor in tumour growth. Novartis Found Symp 240: 186-196, 2001.
32. Baranes D, Lopez-Garcia JC, Chen M, Bailey CH and Kandel ER: Reconstitution of the hippocampal mossy fiber and associational-commissural pathways in a novel dissociated cell culture system. Proc Natl Acad Sci USA 93: 4706-4711, 1996.
33. Denizot F and Lang R: Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 89: 271-277, 1986.
34. Vindelov L and Christensen IJ: An integrated set of methods for routine flow cytometric DNA analysis. Methods Cell Biol 33: 127-137, 1990.
35. Fernando JB and Costa AF: Small cell lung cancer - state of the art and future perspectives. Rev Port Pneumol 13: 587-604, 2007.
36. Fischer B and Arcaro A: Current status of clinical trials for small cell lung cancer. Rev Recent Clin Trials 3: 40-61, 2008.
37. Stordal B and Davey M: Understanding cisplatin resistance using cellular models. IUBMB Life 59: 696-699, 2007.
38. Turturro F, Lawson M, Friday E and Welbourne T: Targeting the Na(+)/H(+) exchanger: an old concept with new perspectives in the treatment of hematological malignancies. Leuk Res 31: 1449-1450, 2007.
39. Wu GM, Qian GS, Huang GJ, Li SP, Yao W and Lu JY: The effect of Na(+)/ H(+) exchanger-1 (NHE-1) antisense expression vector on NHE-1 gene expression in human lung adenocarcinoma cells and its biological significance. Chin J Tuberc Respir Dis 27: 191-194, 2004.
40. Glunde K, Dussmann H, Juretschke HP and Leibfritz D: Na(+)/H(+) exchange subtype 1 inhibition during extracellular acidification and hypoxia in glioma cells. J Neurochem 80: 36-44, 2002.
41. + exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J 14: 2185-2197, 2000.